

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of risk management plan for Lanthan Mylan (Lanthanum carbonate)

This is a summary of the risk management plan (RMP) for Lanthan Mylan. The RMP details important risks of lanthanum carbonate, how these risks can be minimised, and how more information will be obtained about lanthanum carbonate's risks and uncertainties (missing information).

Lanthan Mylan's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how it should be used.

I. The medicine and what it is used for

Lanthan Mylan is authorised for in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis and adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥ 1.78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels. It contains lanthanum carbonate as the active substance and it is given by oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Lanthan Mylan together with measures to minimise such risks and the proposed studies for learning more about Lanthan Mylan 's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific Information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the public (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

Risk Management Plan [Lanthanum Carbonate] Version 1.0

In addition to these measures, information about adverse events is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Lanthan Mylan is not yet available, it is listed under ‘missing information’ below.

II.A List of important risks and missing information

Important risks of Lanthan Mylan are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken by patients. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Lanthan Mylan. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine/use in special patient populations etc.);

Table 6 Part VI: Summary of safety concerns

List of important risks and missing information	
Important identified risks	<ul style="list-style-type: none">• Gastrointestinal obstruction, Ileus, Subileus, Gastrointestinal perforation
Important potential risks	<ul style="list-style-type: none">• Lanthanum deposition (e.g. bone, liver)• Systemic allergic reactions• Medication error associated with incompletely chewed/unchewed tablet
Missing information	<ul style="list-style-type: none">• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Lanthan Mylan.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Lanthan Mylan.